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Opioid dependence is largely an undertreated medical
condition in the United States. The introduction of
buprenorphine has created the potential to expand
access to and use of opioid agonist treatment in gener-
alist settings. Physicians, however, often have limited
training and experience providing this type of care. Some
physicians believe having a mentoring relationship with
an experienced provider during their initial introduction
to the use of buprenorphine would ease implementation.
Our goal was to describe the development, implementa-
tion, resources, and evaluation of the Physician Clinical
Support System-Buprenorphine (PCSS-B), a federally
funded program to improve access to and quality of
treatment with buprenorphine. We provide a description
of the PCSS-B, a national network of 88 trained physi-
cian mentors with expertise in buprenorphine treatment
and skills in clinical education. We provide information
regarding the use the PCSS-B core services including
telephone, email and in-person support, a website, clinical
guidances, a warmline and outreach to primary care and
specialty organizations. Between July 2005 and July
2009, 67 mentors and 4 clinical experts reported provid-
ing mentoring services to 632 participants in 48 states,
Washington DC and Puerto Rico. A total of 1,455 contacts
were provided through email (45%), telephone (34%) and
in-person visits (20%). Seventy-six percent of contacts
addressed a clinical issue. Eighteen percent of contacts
addressed a logistical issue. The number of contacts per
participant ranged from1–125. Between August 2005 and
April 2009 there were 72,822 visits to the PCSS-B website
with 179,678 pages viewed. Seven guidances were down-
loaded more than 1000 times. The warmline averaged
more than 100 calls per month. The PCSS-B model
provides support for a mentorship program to assist
non-specialty physicians in the provision of buprenor-
phine andmay serve as amodel for dissemination of other
types of care.
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T he abuse of opioids, including heroin and prescribed painmedications, is a significant health problem in the United
States.1–3 Opioid agonist treatment decreases illicit opioid
use,4–6 yet it is estimated that only 15% of those who need
treatment receive it.7 The introduction of buprenorphine has
created the potential to expand access to opioid agonist
treatment to settings such as general psychiatry and primary
care.8
Buprenorphine, an opioid partial agonist, reduces opioid
cravings, blocks the effects of opioids, and has limited overdose
potential. Despite evidence of its efficacy and safety,9–13 office-
based treatment using buprenorphine has not been as quickly
adopted by U.S. physicians as some had anticipated or was
needed.14–18 According to its manufacturer, approximately
585,000 individual patients (total) received medically super-
vised buprenorphine detoxification or maintenance treatment
over the four year period from 2003 to 2007.19 During the
same period of time approximately 250,000 patients per year
received treatment with methadone.20 Buprenorphine treat-
ment is facilitated through a relatively low number (8,000 to
10,000) of prescribers; therefore it represented a minority of
the opioid agonist treatment provided during this period.21 In
addition, almost half of prescribers are addiction specialists,21
suggesting limited uptake in more general medical practices
such as general psychiatry or primary care.
Research on the uptake of buprenorphine suggests several
factors influence physician interest in prescribing. These
include knowledge and experience; availability of resources
and support; cost and reimbursement; and perceptions re-
garding the challenges of caring for opioid-dependent
patients.18,22–31
Most physicians who qualify to prescribe buprenorphine
under the provisions of Drug Addiction Treatment Act (DATA
2000) do so by completing an 8-hour course on the treatment
of opioid dependence. To date, more than 16,000 U.S. physi-
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cians have completed such a course. Recognizing that it is
impossible to cover all the needed information in such a brief
course, particularly for physicians with little pre-existing
training in the clinical care of addictive disorders, the Sub-
stance Abuse and Mental Health Services Administration/
Center for Substance Abuse Treatment (SAMHSA/CSAT)
funded the Physician Clinical Support System-Buprenorphine
(PCSS-B) to assist with the implementation of buprenorphine
in the U.S. treatment system. The goal of the PCSS-B is to
promote more widespread use of buprenorphine by providing
educational support to physicians interested in offering it as a
treatment option for patients addicted to prescription opioids
and heroin. The primary target audience was all physicians who
had received initial 8-hour training but would benefit from
additional educational support. By creating the educational
support services of the PCSS-B, it was hoped that non-specialist
physicians would be more inclined to undergo training.
The purpose of this article is to describe the development,
implementation, resources, and evaluation of the PCSS-B for
the first 4 years (July 2005–July 2009) of its implementation.
Lessons from the remote mentoring model used within PCSS-B
may be translatable to other medical and treatment issues.
PCSS-B PROGRAM DEVELOPMENT
AND DESCRIPTION
Program Development. The development of the PCSS-B
occurred according to established criteria in medical
education and curriculum development.32 Needs analyses
came from surveys conducted during early physician
trainings28,31,33,34 and evaluations of clinical experience
using buprenorphine.18 These surveys, conducted nationally
on over 2,000 physicians, demonstrated that a substantial
proportion of physicians receiving training were non-addiction
specialists, had limited experience providing opioid agonist
treatment, anticipated significant challenges and specific
concerns with this model of care and were receptive to a
mentorship model and support services that included online
and distance learning techniques. This work, along with
information regarding the characteristics of the learners
derived from federal agencies and specialty medical societies,
provided the rationale for the development of a training and
support system comprised of multiple medical specialties (e.g.
internal medicine, family practice, psychiatry, HIV medicine),
treatment environments (e.g. inpatient, primary care,
medication-free), practice locations (e.g. rural, urban) and
practice types (e.g. private practice, academic, solo-practitioner).
Program Description. We identified specific instructional
strategies based on observed deficits in knowledge, skills, and
attitudes among the potential learners. The components of the
PCSS-B are 1) a national network of trained physician mentors
with expertise in buprenorphine treatment and skills in
clinical education who are supported by a Medical Director
and a small group of national Clinical Experts, 2) telephone
warmline, 3) clinical guidances, 4) PCSS website (www.
pcssmentor.org), and 5) targeted outreach to state chapters of
primary care organizations. The efforts of the PCSS-B are
overseen by a Steering Committee composed of representatives
from leading addiction medicine societies, organizations that
represent the target physician populations, and the federal
government (Table 1).
As of late 2009, the PCSS-B included 88 mentors around
the U.S. and Puerto Rico. The mentors were chosen by the
Medical Director and the Clinical Experts based on the
individual’s knowledge of opioid dependence, experience using
buprenorphine according to its FDA approved indications,
teaching ability, and availability for contact with PCSS-B
participants (those in need of mentor services) by telephone,
email, and/or in person (to allow participants to observe their
practice using buprenorphine).
The PCSS-B warmline is a national system of telephone
triage that strives to answer queries about buprenorphine or
match participants with mentors within 24 hours. Warmline
staff, non-clinical administrative personnel with support from
a nurse and physician, refer inquirers to the PCSS-B website
and other technical assistance sources, assist in mentor-
participant matching according to specialty/geographic loca-
tion/practice setting, respond to requests for general informa-
tion and information about continuing medical education, and
provide overall mentor-participant administrative support.
The PCSS-B has developed guidances to address common
questions and concerns that have been posed by participants.
The guidances (Table 2) are brief documents that provide
concise and focused discussion of a clinical problem, briefly
review the pertinent medical literature or consensus docu-
ments according to established levels of evidence, and provide
clinical recommendations. All guidances are available through
the PCSS-B website (www.pcssmentor.org). The website also
provides resources on buprenorphine, including federal guide-
lines, links for additional resources and serves as a tool for
data collection, data management, and project management
(i.e. web-based surveys, electronic enrollment into the system
and matching of mentors to participants).
The PCSS-B conducts outreach services to the organiza-
tions of steering committee members, state medical societies
and state chapters of national organizations representing
Internal Medicine and Family Physicians. These services
include postings of descriptions of buprenorphine and PCSS-
B services in electronic and paper media and providing speak-
Table 1. PCSS-B Steering Committee
Addiction Technology Transfer Centers
American Academy of Addiction Psychiatry
American Academy of Child and Adolescent Psychiatry
American Academy of Pediatrics
American Association for the Treatment of Opioid Dependence
American Medical Association
American Osteopathic Academy of Addiction Medicine
American Pain Society
American Psychiatric Association
American Society of Addiction Medicine
Association for Medical Education and Research in Substance Abuse
Center for Substance Abuse Treatment
Health Resources and Services Administration
National Alliance of Advocates for Buprenorphine Treatment
National Alliance of Methadone Advocates
National Association of State Alcohol/Drug Abuse Directors
National Institute on Drug Abuse/Clinical Trials Network
Pacific AIDS Education and Training Centers
Society of General Internal Medicine
The College on Problems of Drug Dependence
The New York Academy of Medicine
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ers for presentations on opioid dependence and the use of
buprenorphine at annual state chapter meetings.
EVALUATION METHODS
Mentors are encouraged, but not required, to log all of their
mentoring activities. As an incentive to provide accurate and
timely data, mentors receive a modest honorarium (ranging
from $200–$2,675/year) based on the number of contacts
registered in a web-based system. Mentors can log into the
web-based system and provide a description of contacts with
their assigned participants. The system collects information on
the geographic location of the contact, type of contact (urgent
versus routine); nature of the questions (clinical or logistical),
mode of contact (email, telephone or on-site visit), the clinical/
logistical areas addressed; and resources used.
Data on the use of PCSS-B clinical guidances are collected
from mentors and using website statistics on downloaded
documents. Website utilization data includes general usage
trends such as counts of unique visitors, pages viewed, hits,
pages most often viewed, and documents downloaded.
All telephone calls to the warmline (but not calls to mentor
physicians) and outreach to primary care activities are
recorded and monitored by PCSS-B staff. Data are collected
on a range of topics including mentor matching requests,
numbers of requests per geographical region and inquiries
related to the SAMHSA physician locator, a web-based tool
that lists physicians who have completed the buprenorphine
training and waiver process. Similarly, a PCSS liaison main-
tains a database of presentations conducted, PCSS resources
distributed, and information published to promote PCSS-B
services to primary care and the public.
Data are primarily collected using self-report through web-
based surveys. Once submitted the data are transferred
through a secure system to the evaluators at The New York
Academy of Medicine. These data are then downloaded and
imported into SPSS v.15 (SPSS Inc., Chicago IL) for analysis
using descriptive statistics. Geographic data are analyzed
using ArcGIS v.8.0 (ESRI, Redlands CA).
RESULTS
PCSS-B Mentors and Participants. The PCSS-B currently has 88
physician-mentors and five clinical experts located in 61
cities across 34 states and Puerto Rico. Nearly all mentors
are certified in the treatment of addictions (81%) and had
more than three years of experience treating opioid
dependence when they joined the PCSS-B (93%). Mentor
specialties include psychiatry (40%), internal medicine (24%),
family medicine (15%), and addiction medicine (14%). Half
identified their primary practice setting as an addiction
treatment program, 25% a private practice and 22% an
academic institution.
Table 2. PCSS-B Clinical Guidances
Adherence, Diversion and Misuse of Sublingual Buprenorphine
Buprenorphine Induction
Management of Psychiatric Medications in Patients Receiving
Buprenorphine/Naloxone
Monitoring of Liver Function Tests and Hepatitis in Patients Receiving
Buprenorphine/Naloxone
Opioid Therapies, HIV disease and Drug Interactions
Physician Billing For Office-Based Treatment of Opioid Dependence
Pregnancy and Buprenorphine Treatment
Psychosocial Aspects of Treatment in Patients Receiving
Buprenorphine/Naloxone
Transfer from Methadone to Buprenorphine
Treatment of Acute Pain in Patients Receiving Buprenorphine/Naloxone
Figure 1. PCSS-B registered participants, contacts, and methadone treatment availability.
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As of July 2009, a total of 4,162 individuals have registered
into the PCSS-B system representing all 50 states, Washington
DC, and Puerto Rico (Fig. 1). PCSS-B participants identify their
specialty as psychiatry (36%), internal medicine (13%), family
medicine (22%), addiction medicine (3%), and other (24%).
Primary practice settings include private practice (49%), aca-
demic setting (8%), addiction treatment programs (5%), and
other (35%). The majority of individuals (76%) self-registered by
phone or through the website or were automatically registered
at a training designed to allow physicians to meet the require-
ments of DATA 2000. Far fewer (5%) were registered into the
system by a mentor. Mentor-registered participants, however,
account for over half of the mentor contacts recorded.
PCSS-B Services Provided (mentor-participant contacts).
Between July 2005 and July 2009, 67 mentors and four clinical
experts reported providing mentoring services to 632 participants
in 48 states (none in Iowa or Utah), Washington DC and Puerto
Rico (Fig. 1). A total of 1,455 contacts were provided through email
(45%), telephone (34%) and in-person visits (20%). Mentors
provided a wide range of services and support. Seventy six
percent of contacts included a clinical issue and 18% included a
logistical issue. The most frequently requested clinical and
logistical support is presented in Table 3. The number of contacts
per participant varied greatly, ranging from 1 to 125. The majority
of participants had five or fewer contacts. Mentors report spending
an average of 5 minutes on preparation, 15 minutes of direct
contact, and about 3 minutes on follow per contact.
Warmline. The PCSS-B warmline responds to an average of 100
inquiries and requests each month via email (55% of inquires),
phone (43%), the website and fax (both < 1%). Overall, just
under half of the requests (49%) were from individuals seeking a
mentor and about a third (31%) were requests for general
information about the PCSS-B. Other requests included
information about buprenorphine courses/trainings (7%),
continuing medical education (5%), the buprenorphine
physician locator (4%), and how to become a mentor (3%).
PCSS Clinical Guidances and Website Use. Mentors reported
distributing PCSS-B clinical guidances in over 10% of
contacts. Between August 2005 and April 2009 there were
72,822 visits to the PCSS-B website with 179,678 pages
viewed. The pages most often viewed were those that included
information on the PCSS-B, the mentors, or resources related
to buprenorphine prescribing and seven guidances were
downloaded more than 1,000 times (Table 4).
Outreach to Primary Care. From 2005–2008, mentors
presented 57 educational workshops to state chapters of
American Academy of Family Physicians (AAFP), American
College of Physicians (ACP), and state medical societies
including a number of states in which access to opioid
treatment is less readily available such as Alaska, Hawaii and
North Dakota. Articles about the PCSS-B have appeared in
over 35 different publications, including USA Today, American
Medical News, American Academy of Family Practice News
Now and Society of General Internal Medicine Forum, as well
as 14 State Medical Association newsletters.
Support for Opioid Treatment in Areas with Limited Availability
of These Services. Geographic data suggest that the PCSS-B
has been successful at providing support for the treatment of
opioid addiction to areas with little or no access to methadone.
In some parts of the United States, buprenorphine offers the
first and only access for pharmacologically-based treatment for
opioid dependence. A goal of the PCSS-B was to promote the
availability of buprenorphine across the country paying
particular attention to those areas without reliable access to
methadone treatment. The program has proven successful at
providing support to physicians in several remote areas and in
states that do not permit methadone maintenance treatment
or have greatly limited access to methadone maintenance
treatment for opioid dependence. This can be seen in the
map (Fig. 1) which plots the locations of PCSS-B contacts and
the availability of methadone treatment.35 In the 13 states with
fewer than five locations to access methadone treatment (AK,
AR, DE, HI, IA, ID, MS, MT, ND, NE, SD, TN, WY), mentors
have had 100 contacts with PCSS-B participants. Additionally
there is evidence to support the role of PCSS-B in providing
support to providers in rural areas which lack methadone
treatment opportunities.
DISCUSSION
Office-based buprenorphine treatment has the potential to
expand access to and use of opioid agonist treatment in non-
Table 3. Most Frequently Provided Clinical and Logistical Support
Clinical %* Logistical %**
Medication dose management 34 Scheduling 43
Dosing induction procedure 32 Payment 35
Induction procedure timing 26 Provider availability 27
Clinical logistical assistance 19 Paperwork 24
Chronic pain 12
*% of clinical contacts, **% of logistical contacts
Table 4. Most Frequently Downloaded PCSS-B Website Documents
Document Downloaded
PCSS-B Guidance: Transfer from Methadone to
Buprenorphine
2573
PCSS-B Guidance: Treatment of Acute Pain
in Patients Receiving Buprenorphine/Naloxone
1967
PCSS-B Guidance: Pregnancy and Buprenorphine
Treatment
1847
PCSS-B Guidance: Monitoring of Liver Function
Tests and Hepatitis in Patients
Receiving Buprenorphine/Naloxone
1735
PCSS-B Guidance: Physician Billing For Office-Based
Treatment of Opioid Dependence
1379
PCSS-B Guidance: Management of Psychiatric
Medications in Patients Receiving
Buprenorphine/Naloxone
1256
DSM IV: Instructions 1062
PCSS-B Guidance: Opioid Therapies, HIV Disease
and Drug Interactions
1021
COWS - Clinical Opiate Withdrawal Scale 930
Tip 40: Clinical Guidelines for the Use of
Buprenorphine
920
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specialty settings. Recent research suggests several factors
affect treatment uptake including: physician knowledge and
experience; availability of resources and support; cost and
reimbursement; and a perception of attracting patients with
significant psychosocial needs. The PCSS-B was developed to
address the first of these by improving physician knowledge
and linking physicians to experienced prescribers. Our results
indicate that the PCSS-B has been able to disseminate
information regarding the appropriate use of buprenorphine
through email, telephone, and in-person support to partici-
pants in 48 states, Washington DC, and Puerto Rico. In
particular, support has focused on both clinical (medication
dose management, dosing induction procedure, induction
procedure timing, clinical logistical assistance, and chronic
pain) and logistical (scheduling, payment, provider availability,
paperwork, and medication supply) issues related to providing
buprenorphine treatment.
Mentoring has been shown to be an effective method of
transferring knowledge and skills in many contexts. While not
addiction specific, the use of mentor relationships in the
Association for Australian Rural Nurses’ Mentor Development
and Support Project resulted in enhanced knowledge, skills,
and confidence among nurses in rural and remote areas.36 The
shared care concept of United Kingdom is another approach
that has shown some success in promoting addiction treat-
ment in primary care.37 In one pilot program, specialists
nurses trained in addiction were successfully used in rural
primary care to provide support to general practitioners. In
this instance nurses were able to provide important support
and expertise to physicians who lacked addiction training,
reduce physician workload, improve communication with
pharmacists, and improve client satisfaction.38 The PCSS-B
was inspired and components modeled after the National HIV/
AIDS Clinicians’ Consultation Center established in the early
1990’s to support HIV treatment.39
Our data are subject to several limitations. First, as a
descriptive study, without a control condition or patient level
data, we are not able to assess the true impact of the PCSS-B on
care quality or buprenorphine treatment expansion. As such it is
not possible to quantify the impact of the PCSS-B on population
health. Nonetheless, anecdotal information derived from the
mentors supports an interpretation that for those participants
who accessed the system, buprenorphine treatment was facili-
tated and likely more consistent with guidelines. Second, while
the sample incorporates a diverse range of physicianswith regard
to geography, practice setting, clinical background and experi-
ence, they are not representative of all physicians trained to
prescribe buprenorphine. The findings are further limited by the
fact that all data collected were by self-report using a web-based
evaluation system. The burden of reporting services rested
entirely on the physician mentors. While the web-based system
was designed to be straight forward, the technology and time
required to catalogue events proved challenging for some. We
note that this program did not provide market-value reimburse-
ment to mentors for their time and effort and believe that many
mentors were motivated to participate based on their commit-
ment to the field and concern over the appropriate implementa-
tion of buprenorphine treatment. Based on conversations with
mentors, we estimate that we were able to collect 33–50% of the
total PCSS-B mentor-participant contacts. To improve data
collection, the mechanism of apportioning honorariums to
mentors has been modified to more directly reflect the number
of recorded contacts. It appears that not all registered partici-
pantswent on to receivementoring services and that participants
who were registered by mentors had the highest use of services.
This implies that strategies to foster a close connection between
participants and mentors may increase use of PCSS-B services.
Despite these limitations, these data do provide important
insight into physician educational needs with respect to office-
based opioid treatment. They also demonstrate the feasibility
of implementing a national system of mentors positioned to
provide ongoing education and support to facilitate and
promote addiction treatment in non-specialty treatment set-
tings. We believe the most immediate lessons that have been
learned from the PCSS-B are the feasibility, acceptability, and use
of expert mentoring services via email, telephone, and on-site
visitation in the practice of medicine. These types of support
services may be most appropriate in situations in which knowl-
edge, skills and attitudes are not learned in medical school or
residency, yet are needed by practicing clinicians. The examples
of HIV care and buprenorphine treatment are emblematic of this
type of need. Based on the experience with the PCSS-B,
SAMHSA/CSAT have funded the implementation of a parallel
program designed to improve the quality of care among patients
receiving methadone in opioid treatment programs, pain prac-
tices, and primary care—the Physician Clinical Support System
for Methadone (PCSS-M). For more information on this program
see www.pcssmethadone.org.
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